The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

The present disclosure relates to a pharmaceutical composition for preventing or treating statin-induced adverse effects or a pharmaceutical composition for co-administration with statin, the pharmaceutical composition containing, as an active ingredient, at least one selected from the group consisting of an isoprenoid-based compound, zaragozic acid, terbinafine, and ketoconazole. The pharmaceutical composition according to the present disclosure may prevent and/or treat adverse statin effects that can be induced by statin, that is, can be induced at any time by oxisterols present at abnormal levels in the body. The pharmaceutical composition can not only treat but also prevent the adverse effects of various statin therapeutics whose use has recently increased rapidly, and thus it is expected that the pharmaceutical composition can be widely used for various diseases and the utilization thereof can further be increased.

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.

The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

The present invention relates to mineral micro-particles comprising phytate (inositol hexaphosphate, IP6). More particularly, the invention provides salts of phytic acid with multivalent metal ions such as Ca.sup.2+ and Mg.sup.2+ for use in biomolecules delivery or adsorption systems, methods for their production and uses thereof, such as for use as a vaccine adjuvant.

The present invention relates to mineral micro-particles comprising phytate (inositol hexaphosphate, IP6). More particularly, the invention provides salts of phytic acid with multivalent metal ions such as Ca.sup.2+ and Mg.sup.2+ for use in biomolecules delivery or adsorption systems, methods for their production and uses thereof, such as for use as a vaccine adjuvant.

A pharmaceutical composition is provided which contains a phospholipid-containing composition which antagonizes toll-like receptors 1, 2, 3, 6, 7, 8 and 10. The phospholipid-containing composition consists of regioisomers and stereoisomers of palmitoyloleoylphosphatidylglycerol (POPG) consisting of at least 80% of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) or a salt thereof, and no more than 20% of its regioisomer 1-oleoyl-2-palmitoyl-sn-glycero-3-phospho-(T-rac-glycerol) or a salt thereof. The phospholipid-containing composition also has enantiomeric enrichment with at least 51% of the dextro rotatory isomer at the sn-2 position of the terminal glycerol moiety.